Retrospective Study of Effect of Adjuvant Chemoradiation of Gastric Carcinoma on Local Control and Survival
NCT ID: NCT05287672
Last Updated: 2022-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2022-06-30
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The American Cancer Society estimates that about 26,560 cases of stomach cancer (16,160 in men and 10,400 in women) will be diagnosed in 2021. Median age at diagnosis is 68 years.
Decreases in gastric cancer have been attributed in part to widespread use of refrigeration. Other factors likely contributing to the decline in stomach cancer rates include lower rates of chronic Helicobacter pylori infection, thanks to improved sanitation and use of antibiotics, and increased screening in some countries.
Surgical resection is the principal therapy for gastric cancer, as it offers the only potential for cure.
Neoadjuvant chemotherapy has an established role in the management of gastric cancer. Perioperative chemotherapy, or postoperative chemotherapy plus chemoradiation, are preferred for localized gastric cancer. Because of lower toxicity, two-drug cytotoxic regimens are preferred for patients with advanced disease.
Adjuvant radiotherapy is associated with improvements in both overall and relapse-free survival and reductions in locoregional failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genomic and Dietary Aspects in Gastric Cancer Risk
NCT05934058
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
NCT03027427
Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
NCT03425058
Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
NCT03632746
Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
NCT07101666
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The American Cancer Society estimates that about 26,560 cases of stomach cancer (16,160 in men and 10,400 in women) will be diagnosed in 2021. Median age at diagnosis is 68 years.
Decreases in gastric cancer have been attributed in part to widespread use of refrigeration. Other factors likely contributing to the decline in stomach cancer rates include lower rates of chronic Helicobacter pylori infection, thanks to improved sanitation and use of antibiotics, and increased screening in some countries.
Surgical resection is the principal therapy for gastric cancer, as it offers the only potential for cure.
Neoadjuvant chemotherapy has an established role in the management of gastric cancer. Perioperative chemotherapy, or postoperative chemotherapy plus chemoradiation, are preferred for localized gastric cancer. Because of lower toxicity, two-drug cytotoxic regimens are preferred for patients with advanced disease.
Adjuvant radiotherapy is associated with improvements in both overall and relapse-free survival and reductions in locoregional failure.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The World Health Organization Performance score 0-2.
3. Haemoglobin at least 10g/dl.
4. White blood cells at least 3000/mm3.
5. Platelets count at least 100000/mm3.
6. Bilirubin concentration no more than 25% higher than upper limit of normal .
7. Liver enzymes no greater than 2.5 times upper limit of normal.
8. Alkaline phosphatase no greater than 2 times upper limit of normal.
9. Creatinine concentration no more than 25% higher than the upper limit of normal .
Exclusion Criteria
2. Prior abdominal irradiation.
3. Pregnant or nursing female.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Walaa Abdelshafy Ali
assistant lecrurer
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
222
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.